Johnson & Johnson Releases Promising Date For Single-Dose COVID-19 Vaccine

J&J releases COVID-19 vaccine after testing against new virus variants Johnson & Johnson offers new data on their single-dose COVID-19 vaccine tested with the newly emerged virus variants. The...


J&J releases COVID-19 vaccine after testing against new virus variants

Johnson & Johnson offers new data on their single-dose COVID-19 vaccine tested with the newly emerged virus variants. The J&J vaccine data shows promising results being 85% effective against preventing severe illness and 66% effective at preventing symptomatic disease.

The global head of Janssen Research & Development, Dr. Mathai Mammen, M.D., Ph.D., is working closely with the team of scientists developing the J&J COVID-19 vaccine. Mammen disclosed the promising “highly effective” vaccine that is 85% effective against severe cases and 100% effective against hospitalization and death.

Johnson & Johnson released a press statement disclosing the vaccine is safe to take and they are prepared to produce the accessible vaccine to be distributed worldwide. The full package of data will be evaluated by the FDA advisory committee in mid to late-February with the data publicly available.

The J&J vaccine was effective 72% in the U.S., 66% in South America, and 75% in South Africa. The most promising data is 100% protection from COVID-19 related hospitalization or death with a single-dose accessible vaccine.